SAFETY AND PHARMACOKINETICS OF ABI-H3733, A NOVEL 2nd GENERATION HBV CORE PROTEIN INHIBITOR: RESULTS FROM A PHASE 1a STUDY IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Gane, Edward J. [1 ]
Schwabe, Christian [2 ]
Alves, Katia [3 ]
Evanchik, Marc [3 ]
Ma, Julie [3 ]
Zomorodi, Katie [3 ]
Knox, Steven J. [3 ]
Stamm, Luisa M. [3 ]
机构：
[1] Auckland City Hosp, Liver Transplant Unit, Auckland, New Zealand
[2] New Zealand Clin Res, Auckland, New Zealand
[3] Assembly Biosci Inc, San Francisco, CA USA
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
842
引用
收藏
页码：516A / 516A
页数：1
相关论文
共 48 条
  • [31] A PHASE 1 SINGLE ASCENDING DOSE STUDY OF A NOVEL OREXIN 2 RECEPTOR AGONIST, TAK-925, IN HEALTHY VOLUNTEERS (HV) AND SUBJECTS WITH NARCOLEPSY TYPE 1 (NT1) TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC OUTCOMES
    Evans, R.
    Tanaka, S.
    Tanaka, S.
    Touno, S.
    Shimizu, K.
    Sakui, S.
    Wu, J.
    Faessel, H.
    Hang, Y.
    Alexander, R.
    Rosen, L.
    Hartman, D.
    SLEEP MEDICINE, 2019, 64 : S105 - S106
  • [32] First-in-human results from a phase 1 single- and multiple-ascending dose study in healthy participants assessing the safety, pharmacokinetics, and pharmacodynamics of the interleukin-17A inhibitor JNJ-81241459
    Ling, I.
    Leung, M.
    Piantone, A.
    Sinha, V.
    Song, D.
    Scott, B.
    Pryor, M.
    Verbruggen, K.
    La, D.
    Tikhonov, I.
    Ceulemans, K.
    Nischal, S.
    Polak, M.
    Eidam, P.
    Goldberg, S.
    Rao, R.
    Yang, Y-W
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S375 - S375
  • [33] Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study
    Wang, Yuhao
    Yu, Chao
    Hu, Mengyue
    Wang, Lu
    Chen, Meixia
    Liu, Hanmo
    Wu, Nan
    Hou, Jie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [34] Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: Results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers
    Addy, Carol
    Li, Susie
    Agrawal, Nancy
    Stone, Julie
    Majumdar, Anup
    Zhong, Ling
    Li, Hankun
    Yuan, Jinyu
    Maes, Andrea
    Rothenberg, Paul
    Cote, Josee
    Rosko, Kim
    Cummings, Corinne
    Warrington, Steven
    Boyce, Malcolm
    Gottesdiener, Keith
    Stoch, Aubrey
    Wagner, John
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (04): : 418 - 427
  • [35] A phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of escalating single doses of R7025, a novel pegylated interferon α compared to placebo and peginterferon α 2A (40KD) (Pegasys®) in healthy volunteers
    Brennan, Barbara
    Robson, Richard
    Rodriguez, Ignacio
    Symons, Julian
    Huang, Jane
    Chan, Margaret
    Blotner, Steven
    Jennings, Natanya
    Rawal, Bina
    Brunda, Michael
    Hooper, Greg
    Rakhit, Ashok
    Nutley, Roche
    HEPATOLOGY, 2007, 46 (04) : 851A - 852A
  • [36] Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab′)2 fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study
    Bal, Celine
    Herbreteau, Cecile H.
    Buchy, Philippe
    Rith, Sareth
    Zaid, Masliza
    Kristanto, William
    Han, Velda
    Reynaud, Charlotte
    Granjard, Patrick
    Lepine, Bertrand
    Durand, Caroline
    Tambyah, Paul A.
    LANCET INFECTIOUS DISEASES, 2015, 15 (03): : 285 - 292
  • [37] Clinical Phase 1b/2 Study Results for Safety, Pharmacokinetics, and Efficacy of ND-L02-s0201, a Novel Targeted Lipid Nanoparticle (LNP) Delivering HSP47 siRNA for the Treatment of Patients with Advanced Liver Fibrosis
    Lawitz, Eric
    Balabanska, Rozalina I.
    Charles, Edgar D.
    Friedman, Scott L.
    Gutierrez, Julio A.
    Niitsu, Yoshiro
    Poordad, Fred
    Sanyal, Arun J.
    Tanaka, Yasunobu
    Thienel, Ulrich
    Ying, Wenbin
    Maruyama, Kageshi
    HEPATOLOGY, 2017, 66 : 237A - 237A
  • [38] RESULTS FROM A PHASE II STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB IN PATIENTS WITH PD-L1 UNSELECTED METASTATIC 2ND LINE HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Pousa, Antonio Lopez
    Felip, Enriqueta
    Forster, Martin
    Doger, Bernard
    Roxburgh, Patricia
    Bajaj, Pawan
    Peguero, Julio
    Carcereny, Enric
    Krebs, Matthew
    Mueller, Christian
    Triebel, Frederic
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A386 - A386
  • [39] A Novel Dual Covalent and Non-Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase LP-168 in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: Safety and Efficacy Results from a Phase 1 Study
    Song, Yuqin
    Cai, Qingqing
    Jiang, Ming
    Zhang, Lei
    Sun, Xiuhua
    Jin, Zhengming
    Li, Lanfang
    Jing, Hongmei
    Peng, Zhigang
    Yang, Haiyan
    Qi, Junyuan
    Zhou, Hui
    Yang, Wei
    Zhou, Min
    Ji, Chunyan
    Xu, Wei
    Ding, Kaiyang
    Yu, Li
    Wang, Zheng
    Liu, Nawei
    Lou, Yejiang
    Shen, Yue
    Chen, Yi
    Tan, Fenlai
    Zhu, Jun
    BLOOD, 2023, 142
  • [40] Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
    Forster, M.
    Felip, E.
    Doger, B.
    Lopez Pousa, A.
    Carcereny, E.
    Bajaj, P.
    Church, M.
    Peguero, J.
    Roxburgh, P.
    Triebel, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S667 - S667
12345